Stefania De Lorenzo
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 13, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: November 22, 2025
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab.
Journal: Scientific reports
Published: April 04, 2025
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: April 18, 2024
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
Journal: British journal of haematology
Published: April 11, 2024
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma.
Journal: Chinese clinical oncology
Published: February 29, 2024
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Journal: Life (Basel, Switzerland)
Published: September 28, 2023
Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study.
Journal: BJS open
Published: April 28, 2023
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis.
Journal: Current oncology (Toronto, Ont.)
Published: December 03, 2022
Last Updated: 09/26/2026